Our Pharma Insights Blog
From vaccines to cancer therapy, biologics are transforming how we treat disease. They don’t just…
The FDA approved 5 drugs in March 2026. The approved drugs span across fields like…
With 1 drug approved in January 2026, we saw a great hike in the approval…
Understanding when a generic or biosimilar opportunity truly opens is rarely straightforward. Regulatory exclusivity and…
The rare disease landscape has hit a significant milestone early in 2026. On January 12th,…
One wrong decision when selecting an enteral feeding tube supplier can disrupt patient care overnight.…
In 2025, the US FDA approved 11 New Biological Entities (NBEs), representing a significant milestone…
In 2025, the US FDA approved 45 new drugs, including 34 New Chemical Entities (NCEs)…
In pharmaceutical development, choosing the right regulatory pathway can significantly influence timelines, costs, and overall…
Every breakthrough medication starts somewhere. That somewhere is either a New Chemical Entity (NCE) or…
A Reference Listed Drug (RLD) is an FDA-approved drug product identified in the Orange Book…
Biosimilars and generics are both affordable alternatives to brand-name medications. These drugs play a crucial…